Immunodynamics of basiliximab in liver allograft recipient under continuous hemodiafiltration [6]

Transplantation

Volumn 77, Issue 9 SUPPL., 2004, Pages 1477-1478

  Eguchi, Susumu ^a   Yanaga, Katsuhiko ^a   Okudaira, Sadayuki ^a   Miyamoto, Shungo ^a   Itoh, Yuichiro ^a   Inuo, Hiroyuki ^a   Yamanouchi, Kohsho ^a   Hamada, Takayuki ^a   Furui, Junichiro ^a   Kanematsu, Takashi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE;

ADULT; CASE REPORT; CONTINUOUS HEMODIAFILTRATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; GRAFT REJECTION; HEMOFILTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; HEMODIAFILTRATION; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HOMOLOGOUS;

EID: 19244365752     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000122186.36120.6B     Document Type: Letter

References (5)

1. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132.
2. Takahira S, Kanno Y, Okada H, et al. Improved outcome prediction for patients with multiple organ failure undergoing continuous hemodiafiltration. Ther Apher 2001; 5: 31.
3. Parzer S, Balcke P, Mannhalter C. Plasma protein adsorption to hemodialysis membranes: studies in an in vitro model. J Biomed Master Res 1993; 27: 455.
4. Okechukwu CN, Meier-Kriesche HU, Armstrong D, et al. Removal of basiliximab by plasmapheresis. Am J Kidney Dis 2001; 37: E11.
5. Kovarik J, Breidenbach T, Gerbeau C, et al. Disposition and immunodynamics of basiliximab in liver allograft recipients. Clin Pharmacol Ther 1998; 64: 66.